Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | GSK3B | P49841 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286956 | 0.86 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22311826 | 0.86 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22312721 | 0.85 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22311982 | 0.84 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22312445 | 0.84 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22311453 | 0.84 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22312695 | 0.83 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22312365 | 0.83 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22286838 | 0.81 | CCNE1 (1.00) | CCNE1CDK2GSK3B | |
| SCHEMBL22286832 | 0.81 | CCNE1 (1.00) | CCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
| US-11014911-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885GSK3B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.